Viread and Baraclude are expecting a competition against generics
The benefit range of the chronic hepatitis type B treatment ‘Viread (generic name: tenofovir)’ has been extended. This would be a favorable condition for the product prior to competition against its competing drug ‘Baraclude (generic name: entecavir)’ that will be poured out into the market next ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
